• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Hoth Therapeutics, Inc.

    3/18/21 7:03:36 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G 1 c101332_sc13g.htm

     

    SECURITIES AND EXCHANGE
    COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO § 240.13d-2.

     

    (Amendment No.   )*

     

    Hoth Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    44148G105

    (CUSIP Number)

     

    March 10, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     
    CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    4.0%
      (12) Type of Reporting Person (See Instructions)
    OO

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power

    354,430 shares of Common Stock
    354,430 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (6) Shared Voting Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    (7)

    Sole Dispositive Power
    354,430 shares of Common Stock

    354,430 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (8) Shared Dispositive Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person
    1,265,822 shares of Common Stock
    1,265,822 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    5.5%
      (12) Type of Reporting Person (See Instructions)
    IN; HC

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6) Shared Voting Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    (7) Sole Dispositive Power
    0
     
    (8) Shared Dispositive Power
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    911,392 shares of Common Stock
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
      (11) Percent of Class Represented by Amount in Row (9)
    4.0%
      (12) Type of Reporting Person (See Instructions)
    IN

     

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

     
    CUSIP No: 44148G105
     
    Item 1.
      (a)  Name of Issuer
    Hoth Therapeutics, Inc., a Nevada corporation (the “Company”)
      (b) Address of Issuer’s Principal Executive Offices
    1 Rockefeller Plaza, Suite 1039, New York, NY 10020
     
    Item 2 (a). Name of Person Filing
    Item 2 (b). Address of Principal Business Office or, if none, Residence 
    Item 2 (c).

    Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Iroquois Capital Management L.L.C., a Delaware limited liability company (“Iroquois”), (ii) Richard Abbe, an individual who is a citizen of the United States of America and (iii) Kimberly Page, an individual who is a citizen of the United States of America (“Mr. Abbe” and “Ms. Page,” together with Iroquois, the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of all of the Reporting Persons is 125 Park Avenue, 25th Floor New York, NY 10017.

     

    Item 2 (d)

    Title of Class of Securities
    Common Stock, par value $0.0001 per share

     

    Item 2 (e)

    CUSIP Number
    44148G105

     

     
    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g)  o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h)  o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) o

    Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Item 4.    Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 22,776,940 shares of Common Stock issued and outstanding as of March 11, 2021 as disclosed in the Company’s Annual Report on Form 10-K filed on March 16, 2021, and assumes the exercise of the Company's reported warrants (the “Reported Warrants”) subject to the Blocker (as defined below).

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Blocker”), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blocker. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise any of the Reported Warrants due to the Blocker.

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held 911,392 shares of Common Stock and Reported Warrants to purchase 911,392 shares of Common Stock (subject to the Blocker) and Iroquois Capital Investment Group LLC (“ICIG”) held 354,430 shares of Common Stock and Reported Warrants to purchase 354,430 shares of Common Stock (subject to the Blocker).

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blocker) held by, Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock held by and underlying the Reported Warrants (each subject to the Blocker) held by, Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     

    Item 5.    Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  o

     

    Item 6.    Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.    Identification and Classification of Members of the Group

     

    See Exhibit 1.

     

    Item 9.    Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.    Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 17, 2021

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
           
      By:    /s/ Richard Abbe  
        Richard Abbe, President  

     

        /s/ Richard Abbe  
      Richard Abbe  
         
        /s/ Kimberly Page  
      Kimberly Page  
     

    EXHIBIT INDEX

     

    Exhibit 1  Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
     

    Exhibit 1

     

    JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

     

    Date: March 17, 2021

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
           
      By:    /s/ Richard Abbe  
        Richard Abbe, President  

     

      /s/ Richard Abbe  
      Richard Abbe  
         
      /s/ Kimberly Page  
      Kimberly Page  
     
    Get the next $HOTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

    NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi). The submission marks a major regulatory inflection point for Hoth, reinforcing its commitment to a global clinical strategy and unlocking the potential to address a vast oncology supp

    9/10/25 8:29:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

    NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability. This adoption positions Hoth at the forefront of AI-driven drug development, reinforcing its commitment to cutting-edge innovation and accelerated therapeutic discovery. PredictBBB.ai, part of Lantern's RADR® AI platform, is a game-changing techno

    9/4/25 8:16:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, a clean safety profile, and new GLP-validated bioanalytical results that exceeded internationally recognized regulatory thresholds. Preclinical Efficacy & Safety Highlights Rapid Tumor Kill: HT-KIT triggered significant tumor cell death in preclinical models of gastrointestinal stroma

    9/2/25 8:16:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb was granted 800,000 shares and covered exercise/tax liability with 310,744 shares, increasing direct ownership by 842% to 547,387 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/28/25 6:48:36 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Camarra Christopher Michael

    3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    5/21/25 5:30:18 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Knie Robb

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    1/15/25 4:15:55 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    SEC Filings

    View All

    Hoth Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    8/22/25 4:15:38 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Hoth Therapeutics Inc.

    10-Q - Hoth Therapeutics, Inc. (0001711786) (Filer)

    8/12/25 4:15:47 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Hoth Therapeutics Inc.

    S-8 - Hoth Therapeutics, Inc. (0001711786) (Filer)

    8/5/25 4:27:24 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/19/24 8:00:03 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

    Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

    6/5/25 8:12:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

    1/31/22 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/24 2:47:32 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hoth Therapeutics Inc.

    SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/23 12:55:35 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care